凝血调节蛋白α治疗脓毒症诱导的弥散性血管内凝血的治疗效应与不良效应
本研究在脓毒症诱导弥散性血管内凝血(DIC)患者中计算凝血调节蛋白(TM)α的血浆谷浓度,并以600 ng/mL为界分为低浓度组(14例)和高浓度组(35例)。高浓度组给药4天后日本急诊医学会DIC诊断标准评分较基线下降2.06分,低浓度组下降0.71分,差异显著。高浓度组90天生存率85.4%,低浓度组49.0%(HR 0.27,95%CI 0.09-0.86)。两组严重出血发生率无显著差异。作者认为脓毒症DIC治疗中TMα推荐血浆浓度高于600 ng/mL,达到该浓度所需剂量为380 U/kg(0.06 mg/kg)。
要点
- 以血浆谷浓度600 ng/mL为界分组,高浓度组(35例)DIC评分4天较基线下降2.06分,低浓度组(14例)下降0.71分。
- 高浓度组90天生存率85.4%,低浓度组49.0%,HR 0.27(95%CI 0.09-0.86)。
- 两组严重出血发生率无显著差异。
- 作者认为脓毒症DIC治疗中TMα推荐血浆浓度高于600 ng/mL,所需剂量为380 U/kg(0.06 mg/kg)。
适用人群与场景
- 脓毒症诱导的弥散性血管内凝血(DIC)患者,来自日本,纳入低浓度组14例和高浓度组35例。
诊断标准与关键阈值
- 采用日本急诊医学会DIC诊断标准评分评估DIC严重程度,于TMα给药后第4天评估。
- 以TMα血浆谷浓度600 ng/mL为界,分为低浓度组(<600 ng/mL)和高浓度组(≥600 ng/mL)。
处置流程与药物剂量
- TMα给药剂量380 U/kg(0.06 mg/kg)可达到血浆谷浓度高于600 ng/mL。
研究设计与关键结果
- 研究计算脓毒症DIC患者TMα血浆谷浓度,按600 ng/mL分为低浓度组14例和高浓度组35例。
- 高浓度组给药4天后日本急诊医学会DIC诊断标准评分较基线下降2.06分,低浓度组下降0.71分,差异显著。
- 高浓度组90天生存率85.4%,低浓度组49.0%,HR 0.27(95%CI 0.09-0.86)。
- 两组严重出血发生率无显著差异。
- 作者认为脓毒症DIC治疗中TMα推荐血浆浓度高于600 ng/mL,达到该浓度所需剂量为380 U/kg(0.06 mg/kg)。
证据类型、等级与局限
- 研究类型:未明确报告研究设计类型,原文报告为脓毒症DIC患者TMα血浆谷浓度与疗效及出血不良事件关系的研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为脓毒症DIC治疗中TMα推荐血浆浓度高于600 ng/mL,达到该浓度所需剂量为380 U/kg(0.06 mg/kg)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
In the treatment of disseminated intravascular coagulation (DIC), which is a complication of underlying diseases such as infections and malignant tumors, effective plasma concentrations of thrombomodulin (TM) alfa range from 300 to 900 ng/mL; however, appropriate concentrations when treating sepsis-induced DIC are unknown. Thus, our aim was to determine the relationship between plasma concentrations of TM alfa and its therapeutic effects, and hemorrhagic adverse events. First, we calculated the plasma trough concentrations of TM alfa in septic DIC patients. Next, we divided patients into two groups according to their plasma concentrations into a low- and high-concentration group based on a cut-off value of 600 ng/mL. Fourteen and 35 patients were included in the low- and high-concentration groups, respectively. The Japanese Association for Acute Medicine DIC diagnostic criteria score 4 days after TM alfa administration decreased significantly by 2.06 points from baseline in the high-concentration group compared with 0.71 points in the low-concentration group. The 90-day survival rate was significantly higher in the high-concentration group (85.4%) than in the low-concentration group (49.0%) (hazard ratio, 0.27; 95% confidence interval: 0.09-0.86). In contrast, the incidence of serious hemorrhage was not significantly different between the groups. The recommended plasma concentration of TM alfa in the treatment of septic DIC was determined to be higher than 600 ng/mL, and a dose of 380 U/kg (0.06 mg/kg) was necessary to achieve this concentration.
参考来源
- Imaura M, Tsumori M, Nagase S, et al. Therapeutic and Adverse Effects of Thrombomodulin Alfa to Treat Sepsis-Induced Disseminated Intravascular Coagulation. Shock. 2020. PMID: 31764622. doi:10.1097/SHK.0000000000001477
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。